458 related articles for article (PubMed ID: 23258740)
1. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of autophagy and the AKT pathway in prostate cancer.
Lamoureux F; Zoubeidi A
Autophagy; 2013 Jul; 9(7):1119-20. PubMed ID: 23670050
[TBL] [Abstract][Full Text] [Related]
3. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
4. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.
Degtyarev M; De Mazière A; Orr C; Lin J; Lee BB; Tien JY; Prior WW; van Dijk S; Wu H; Gray DC; Davis DP; Stern HM; Murray LJ; Hoeflich KP; Klumperman J; Friedman LS; Lin K
J Cell Biol; 2008 Oct; 183(1):101-16. PubMed ID: 18838554
[TBL] [Abstract][Full Text] [Related]
5. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
[TBL] [Abstract][Full Text] [Related]
6. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
7. Akt and autophagy cooperate to promote survival of drug-resistant glioma.
Fan QW; Cheng C; Hackett C; Feldman M; Houseman BT; Nicolaides T; Haas-Kogan D; James CD; Oakes SA; Debnath J; Shokat KM; Weiss WA
Sci Signal; 2010 Nov; 3(147):ra81. PubMed ID: 21062993
[TBL] [Abstract][Full Text] [Related]
8. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
9. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
10. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
11. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
12. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
14. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
15. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Festuccia C; Gravina GL; Muzi P; Millimaggi D; Dolo V; Vicentini C; Bologna M
Prostate; 2008 Jun; 68(9):965-74. PubMed ID: 18361408
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
17. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.
Yates JW; Dudley P; Cheng J; D'Cruz C; Davies BR
Cancer Chemother Pharmacol; 2015 Aug; 76(2):343-56. PubMed ID: 26092323
[TBL] [Abstract][Full Text] [Related]
18. Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis.
Choi AR; Jung MJ; Kim JH; Yoon S
Anticancer Res; 2015 Sep; 35(9):4741-7. PubMed ID: 26254364
[TBL] [Abstract][Full Text] [Related]
19. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
[TBL] [Abstract][Full Text] [Related]
20. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]